Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Toripalimab-tpzi + YH001 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Toripalimab-tpzi | Loqtorz | Toripalimab|JS001|JS-001|TAB001 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 122 | Loqtorz (toripalimab-tpzi) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response and decreased tumor growth (PMID: 28317872; PMID: 32277740, PMID: 32406293, PMID: 32321714). Loqtorz (toripalimab-tpzi) in combination with cisplatin and gemcitabine is FDA-approved for use in adult patients with metastatic or recurrent, locally advanced nasopharyngeal carcinoma (FDA.gov). |
YH001 | YH 001|YH-001 | CTLA4 Antibody 31 | YH001 is a humanized anti-CTLA4 antibody that may block immunosuppression in tumor microenvironment and enhance antitumor immune response (J Clin Oncol 39, no. 15_suppl (May 20, 2021) 2577-2577). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04357756 | Phase I | Toripalimab-tpzi + YH001 | A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors | Completed | AUS | 0 |
NCT05212922 | Phase II | Toripalimab-tpzi + YH001 | A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC (YH001) | Withdrawn | AUT | AUS | 3 |